Neptune to Hold Conference Call
2013年1月15日 - 12:44AM
Neptune Technologies & Bioressources Inc.
("
Neptune") (Nasdaq:NEPT) (TSX:NTB) will be
holding a conference call on Thursday January 17 at 4:30pm ET. The
call will focus on the presentation of the financial results for
the third quarter ended November 30, 2012, and will also provide an
opportunity to comment on the status of its previously disclosed
action plan to resume operations and supply customers.
The conference call hosts will be Henri Harland, President &
CEO, and André Godin, CFO.
To access the conference call by phone within Canada & the
U.S., the toll‐free number is 1‐877-380-5664. Outside Canada and
the U.S., dial 1‐631-813-4882.
Conference call details:
Conference Topic: Neptune Technologies & Bioressources Third
Quarter 2012 Earnings Call
Conference ID: 86940717
Management will accept questions related to the financial
results and its operations by telephone during the Q&A period
at the end of the presentation. Questions can also be forwarded in
advance or during the presentation to
f.harland@neptunebiotech.com.
An archived recording of the conference call will be available
on Neptune's website (www.neptunebiotech.com) shortly after the
call.
The unaudited interim consolidated financial statements of
Neptune as at and for the interim period ended November 30, 2012
and related MD&A will be made available on SEDAR at
www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on Neptune's
website at http://www.neptunebiotech.com after market close
on January 14th, 2013.
About Neptune Technologies & Bioressources
Inc.
Neptune is a biotechnology company engaged primarily in the
development and commercialization of marine-derived omega-3
polyunsaturated fatty acids, or PUFAs. Neptune has a patented
process of extracting oils from Antarctic krill, which omega-3
PUFAs are then principally sold as bulk oil to Neptune's
distributors who commercialize them under their private label
primarily in the U.S., European and Asian neutraceutical markets.
Neptune's lead products, Neptune Krill Oil (NKO®) and ECOKRILL Oil
(EKO™), generally come in capsule form and serve as a dietary
supplement to consumers.
Through its subsidiaries Acasti Pharma (TSX-V:APO) and
NeuroBioPharm, in which Neptune respectively holds 57% and 99% of
the voting rights, Neptune is also pursuing opportunities in the
medical food and prescription drug markets. Acasti and NeuroBio
respectively focus on the research and development of safe and
therapeutically effective compounds for highly prevalent
atherosclerotic conditions, such as cardiometabolic disorders and
cardiovascular diseases, and for neurodegenerative and inflammation
related conditions. Acasti's lead prescription drug candidate is
CaPre®, a purified high omega-3 phospholipid concentrate derived
from Neptune krill oil being developed to address the prevention
and treatment of cardiometabolic disorders, including
hypertriglyceridemia, which is characterized by abnormally high
levels of triglycerides.
Forward Looking Statements
Certain statements included in this press release may be
considered forward-looking information within the meaning of
Canadian securities laws and forward-looking statements within the
meaning of U.S. federal securities laws, both of which we refer to
as forward-looking statements. Such statements involve known and
unknown risks, uncertainties and other factors that may cause
results, performance or achievements to be materially different
from those implied by such statements, and therefore these
statements should not be read as guarantees of future performance
or results. All forward-looking statements are based on Neptune's
current beliefs as well as assumptions made by and information
currently available to Neptune and relate to, among other things,
Neptune's strategy, strategic goals, research and development
activities, research and clinical testing outcome, future
operations, future financial position, future revenues/results,
projected costs, prospects and plans and objectives of
management.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks
and uncertainties identified by Neptune in its amended and restated
annual information form dated September 11, 2012, in its press
release announcing an action plan to resume operations and supply
customers dated November 26, 2012 and in its other public
securities filings available at www.sedar.com and
www.sec.gov/edgar.shtml, actual events may differ materially from
current expectations. Except as required by law, Neptune disclaims
any intention or obligation to update or revise any forward-looking
statements.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 6 2024 まで 7 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 7 2023 まで 7 2024